BioData EU 2018 - Agenda Day 1

 

BioData EU- Day 1

08:55

Opening Remarks

Abel Archundia
09:00

Keynote opening address

09:20

Title Sponsor

Bertrand Bodson
09:40

AI- the future of medicine

Sue Hill
10:00

How the NHS plans to implement precision medicine using AI

10:20

Speed Networking

10:40

Morning Refreshments

11:20

Platinum Sponsor

11:40

Round Tables

Roundtable 1: Biomarker discovery in the world of AICHAIR: Suleiman Khan, Senior Researcher, Institute for Molecular Medicine FinlandRoberto Iacone, CSO/VP, Bright PeakMichael Scharfe, Data Architect, NovartisEnrico Ferrero, Senior Investigator I, Novartis+Roundtable 2: Using Electronic Medical Record (EMR) data to inform big pharma’s drug discovery, development, and marketing processesCHAIR: William Paiva, Executive Director, Center for Health Systems Innovation, Oklahoma State UniversityNicholas Kelley, Research Investigator, Informatics Solutions, Novartis+ Roundtable 3: +Roundtable 4: Data Management and DemocratisationCHAIR: Olivier Leconte, Data Operation Development Units, Global Head, NovartisTorsten Schwede, Director, Data Coordination Centre of the Swiss Personalized Health Network (SPHN), Director, sciCORE - center for scientific computing, University of BaselMoritz Gilsdorf, Senior Scientific Software Engineer, RocheOlivier Roche, Global Data Quality Coordinator, Biology Workflow Team Leader, Roche+Roundtable 5:+Roundtable 6: Accelerating Innovation in PharmaceuticalsCHAIR: Alain Bindels, Innovation task force Leader, RocheKate Merton, Head, JLABS NYC & Boston, Johnson & JohnsonLena Hansson, Principal Scientist, Novo NordiskEnrique Toledo, Senior Scientist, Novo NordiskAndrew Lowe, Senior Scientist, Novo Nordisk+Roundtable 7: Navigating Real World Data & Applied AnalyticsCHAIR: Gabriel Eichler, Data & Analytics Workstream Lead - Kraft Precision Medicine Accelerator, Harvard Business School+Roundtable 8: Sequencing and collaborationCHAIR: Quin Wills, Head of Advanced Genomics, Novo NordiskJan Nygaard Jensen, Scientific Director, Head of Bioinformatics Discovery, Novo NordiskGary Saunders, Human Data Coordinator, Elixir/EBI+Roundtable 9: Using digital technologies in clinical trialsCHAIR: Diego Ardigo, Global Head of Rare Diseases, ChiesiDirk Voelkel, CTO - Innovation & Analytics, GE Healthcare - Life SciencesFlorian Hahne, Senior Investigator, Novartis+Roundtable 10: Using RWD across bordersCHAIR: Eunice Jung, Associate Director of Value Based Medicine, Biogen+Roundtable 11: Examining developments on data privacyCHAIR: Nicola Orlandi, Head Data Privacy Pharma, Novartis InternationalMaria Chiara Atzori, Head of Data Privacy Switzerland, Novartis+Roundtable 12: Emerging Investment Thesis – Engaging results from large scale investmentsCHAIR: Mark Sluijs, Digital Investment Advisory, Merck+Roundtable 13: Managing Genetic DataCHAIR: Jennifer Cham, Lead User Experience Designer, EMBL-EBI+Round table 14: Translational Oncology InformaticsRon Chen, Head of Informatics Asia Pacific and Merck R&D China IT, MSD+Round table 15: Examining device-based data capture and analyticsSteffen Roellinger, SVP - Head Portfolio & Operations, Pharma R&D, Bayer+Round table 16: UN Round Table: Block Chain and Health RecordsKaren Keely, Partner, RARE Sciences+Round table 17: Social determinants for healthcareFreddy Abnousi, Head of Healthcare, Facebook+Round table 18: Title TBCDELL EMC+Round table 19: Title TBCMarkLogic+ Round table 20:Sharing Clinical DataXose Fernandez, Chief Data Officer, Institut Curie
Round table 14: Translational Oncology Informatics
Roundtable 10: Using RWD across borders
Roundtable 11: Examining developments on data privacy
Roundtable 12: Emerging Investment Thesis – Engaging results from large scale investments
Roundtable 13: Topic TBC
Roundtable 1: Biomarker discovery in the world of AI
Suleiman Khan

Suleiman Khan, Senior Reseracher, University of Helsinki

Roundtable 2: Using Electronic Medical Record (EMR) data to inform big pharma’s drug discovery, development, and marketing processes
Roundtable 3: NTT DATA
Roundtable 4: Data Management and Democratisation
Roundtable 5: Western Digital
Roundtable 6: Accelerating Innovation in Pharmaceuticals
Roundtable 7: Navigating Real World Data & Applied Analytics
Roundtable 8: Sequencing and collaboration
Roundtable 9: Using digital technologies in clinical trials
12:30

Networking Lunch

IT, DATA MANAGEMENT AND STORAGE

BIOINFORMATICS

AI, AUTOMATION AND MACHINE LEARNING

BIG DATA IN ONCOLOGY

DATA INTEGRATION & INFRASTRUCTURE

Track 1- IT, DATA MANAGEMENT AND STORAGE
13:30

Chairs Opening Remarks

Track 2- BIOINFORMATICS & GENOMIC TOOLS
13:30

Chairs Opening Remarks

Track 5- DATA INTEGRATION & INFRASTRUCTURE/ BIG DATA IN RARE DISEASES
13:30

Chairs Opening Remarks

Track 1- IT, DATA MANAGEMENT AND STORAGE
13:35

How to make data accessible?

  • Pooling of internal and external data sources for clinical development
  • Overview on business use cases at Novartis, and underlying technology platform(s)
  • Critical enablers of the journey (e.g. agile governance, partner ecosystem, rapid data prototyping)
Track 3- AI, AUTOMATION AND MACHINE LEARNING
13:35

WuXi NextCODE

Track 1- IT, DATA MANAGEMENT AND STORAGE
13:55

Optimizing Big Data Workloads to Accelerate Drug Development

  • Pharmaceutical companies are saddled with legacy systems containing heterogeneous and disparate data. Increasing the ability to share data requires rationalizing and connecting these systems.
  • IT-enabled portfolio management allows data-driven decisions to be made quickly and seamlessly.
  • Responsive, agile, and flexible platform that can leverage a cloud based approach
Track 2- BIOINFORMATICS & GENOMIC TOOLS
13:55

Techniques from Small Molecule Discovery

  • Data diversity, volume and complexity represent challenges for biologics drug discovery
  • Small molecule discovery utilizes advanced analytical techniques such as QSAR, matched-molecular pairs, etc., to predict relationships between structure and activity
  • This talk will discuss adaptation of these techniques to biologics discovery, highlighting successes and potential pitfalls
Track 4- BIG DATA IN ONCOLOGY
13:55

Individumed

Track 5- DATA INTEGRATION & INFRASTRUCTURE/ BIG DATA IN RARE DISEASES
13:55

MarkLogic

Track 1- IT, DATA MANAGEMENT AND STORAGE
14:15

Be Data Ready: the story of Sanofi’s translational data governance

  • What is data governance ?
  • Understanding your data ecosystem: key drivers and enablers
  • The ‘How to’ implementation challenge: a mix of top-down and bottom-up approaches
  • Future vision and perspectives
Track 3- AI, AUTOMATION AND MACHINE LEARNING
14:15

Title to be confirmed

Track 5- DATA INTEGRATION & INFRASTRUCTURE/ BIG DATA IN RARE DISEASES
14:15

Liberating evidence from real world data in the 21st Century: what have we learned from IMI EMIF, and where will IMI EHDEN take us?

  • Insights from the IMI European Medical Information Framework project 2013-2018
  • What is proposed for the IMI European Health Data and Evidence Network 2018-2023
  • Building sustainable infrastructure via federated networks, common data models and data ecosystems
14:35

Refreshment break

IT, DATA MANAGEMENT AND STORAGE

BIOINFORMATICS

AI AND MACHINE LEARNING

BIG DATA IN ONCOLOGY

DATA INTEGRATION & INFRASTRUCTURE

Track 1- IT, DATA MANAGEMENT AND STORAGE
15:15

Chairs Opening Remarks

Track 2- BIOINFORMATICS & GENOMIC TOOLS
15:15

Chairs Opening Remarks

Track 3- AI, AUTOMATION AND MACHINE LEARNING
15:15

Chairs Opening Remarks

Track 4- BIG DATA IN ONCOLOGY
15:15

Chairs Opening Remarks

Track 2- BIOINFORMATICS & GENOMIC TOOLS
15:20

The use of RWD and machine learning in reverse translation

  • Reverse translation is gaining more importance in drug discovery to support application of human data for target-indication prioritization and patient selection
  • Real world data can provide additional source of information to help selecting the right target for the right indication
  • Machine learning applied to real world data can provide enhanced characterization of diseases and patient trajectories supporting more robust reverse translation
Track 5- DATA INTEGRATION & INFRASTRUCTURE/ BIG DATA IN RARE DISEASES
15:20

Towards FAIR data: ELIXIR

Track 2- BIOINFORMATICS & GENOMIC TOOLS
15:40

Role of AI in bioinformatics and Drug Discovery

  • Is AI/ML transforming bioinformatics?
  • Do we have the right data?
  • Examples of using Advanced Analytics
Track 5- DATA INTEGRATION & INFRASTRUCTURE/ BIG DATA IN RARE DISEASES
15:40

Developing the AZ Data Architecture

Track 1- IT, DATA MANAGEMENT AND STORAGE
16:00

NTT Data

Track 2- BIOINFORMATICS & GENOMIC TOOLS
16:00

Copyright Clearance Center

Track 3- AI, AUTOMATION AND MACHINE LEARNING
16:00

Oracle

Track 4- BIG DATA IN ONCOLOGY
16:00

WuXiNextCODE

Track 5- DATA INTEGRATION & INFRASTRUCTURE/ BIG DATA IN RARE DISEASES
16:00

Ontoforce

Track 1- IT, DATA MANAGEMENT AND STORAGE
16:20

Cross Pharma HPC Collaboration to Improve Pharma Research and Scientific Outcomes

  • A decade of successful pre-competitive xPharma HPC collaboration http://www.hpcxpharma.org/
  • Classic HPC platforms for R&D
  • Future-ready data and HPC platforms for clinical and commercial Big Data Mining
Track 3- AI, AUTOMATION AND MACHINE LEARNING
16:20

The Benefits of Bayesian AI

  • Real-world AI systems need to account for uncertainty and reason probabilistically
  • Bayesian methods provide a principled approach to dealing with uncertainty
  • Recent developments in this area will be discussed

Refreshment Break (Drinks to be served)

IT, DATA MANAGEMENT AND STORAGE

BIOINFORMATICS & GENOMIC TOOLS

AI, AUTOMATION AND MACHINE LEARNING

BIG DATA IN ONCOLOGY

BIG DATA IN RARE DISEASES

Track 1- IT, DATA MANAGEMENT AND STORAGE
17:05

Putting data to work in drug discovery - building an AI-enhanced future

Data, information and knowledge management is a critical foundation for building an AI-enhanced future for drug discovery. I will show examples of our work, and in particular discuss how technology interfaces with culture in this area”
Track 2- BIOINFORMATICS & GENOMIC TOOLS
17:05

Insights from MedImmune: Tertiary analysis of genomics data

  • Developing a cohort explorer for comparison of genotype and phenotype
  • Overview of Astrazeneca/MedImmune strategy for using genomics in drug discovery
  • Partnership with DNAnexus
Track 4- BIG DATA IN ONCOLOGY
17:05

The digital Clinical Trial – potential future hybrid trial models

  • Digital Clinical Trial Models
  • Current digitalECMT work
  • Examples of a range of trail types
Track 5- DATA INTEGRATION & INFRASTRUCTURE/ BIG DATA IN RARE DISEASES
17:05

Predictive modeling for rare diseases

Track 1- IT, DATA MANAGEMENT AND STORAGE
17:25

DELL EMC

Track 2- BIOINFORMATICS & GENOMIC TOOLS
17:25

Sponsor Available

Track 3- AI, AUTOMATION AND MACHINE LEARNING
17:25

Pure Storage

Track 4- BIG DATA IN ONCOLOGY
17:25

PerkinElmer

Track 5- DATA INTEGRATION & INFRASTRUCTURE/ BIG DATA IN RARE DISEASES
17:25

WuXiNextCODE

Track 1- IT, DATA MANAGEMENT AND STORAGE
17:45

Ensuring patient centricity within the digital world

  • Keeping data focussed on unmet patient need.
  • Using digital channels to engage HCPs
  • Gathering patient insights for strategic decisions
Track 2- BIOINFORMATICS & GENOMIC TOOLS
17:45

Bioinformatics as a Service: A National Resource to Support Biomedical Research in Qatar

Track 5- DATA INTEGRATION & INFRASTRUCTURE/ BIG DATA IN RARE DISEASES
17:45

Presentation

Track 1- IT, DATA MANAGEMENT AND STORAGE
18:05

Integrating health into your digital life

  • As Healthcare providers, we need to recognize that people who use our services already have a footprint in the digital world, with services, devices and applications which they are comfortable using. Instituting change in this is likely to lead to disengaged users, with fewer beneficial outcomes.
  • The last 20 years have brought with them a tremendous pace of innovation in many industries, and created whole new industries through technology itself. In many cases, these changes have instilled behavior shifts and expectations in users - it is important as healthcare revolutionizes itself to learn from these, to not reinvent the wheel, and accelerate our movement by exploiting benefits and opportunities from other industries.
  • Obtaining meaningful insight on patients is based on a simple reward/effort ratio. In order to minimize the effort of data collection, this must be seamless, transparent and simple from the person’s perspective – integrating with passive monitoring systems and zero-UI systems make data collection easy, while the value of providing actionable, timely and relevant insight to a patient will keep them engaged with the platform and feel like it provides them with value.
Track 2- BIOINFORMATICS & GENOMIC TOOLS
18:05

Bioinformatics as a Service: A National Resource to Support Biomedical Research in QatarMassively parallel single-cell CRISPR sequencing in organoid models

  • Genetic epidemiology and CRISPR screens both still struggle to make highly predictive comments about drug target modifiers (i.e. precision medicine) .
  • Using liver organoid models, while integrating single-cell sequencing with CRISPR, we are dissecting out the cross-talk between metabolic pathways to understand target interactions.
  • The pipeline and novel methods underlying such genetic screens and the types of results bing generated will be presented.
Track 5- DATA INTEGRATION & INFRASTRUCTURE/ BIG DATA IN RARE DISEASES
18:05

Integrating clinical and translational data in trials

18:25

Close of Congress

last published: 20/Jul/18 15:45 GMT

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Alistair Wilmot
+44 (0)207 092 1174

alistair.wilmot@terrapinn.com


To speak:
Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com